The Role of Staging Laparoscopy in Stage IV Gastric Cancer Patients
Digestive Surgery · 2025
DOI: 10.1159/000543489 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Digestive Surgery, 2025. Verfasst von Leonardo Solaini und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, Morgagni-Pierantoni Hospital, University of Bologna, Forlì, Italy. Hauptthemen laut MEDLINE: Stomach Neoplasms, Laparoscopy, Peritoneal Neoplasms, Carcinoma. Die Arbeit nennt 18 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Evidence regarding staging laparoscopy (SL) for clinical metastatic (cM+) gastric cancer (GC) patients is limited. Recently, an Italian Gastric Cancer Research Group (GIRCG) study showed SL changed peritoneal status in over 20% of cases. This study aimed to evaluate SL’s role in cM+ patients and refine its indications.
Methods
Clinical data of cM+ GC patients who underwent SL between 2010 and 2022 at nine GIRCG centers were retrospectively analyzed. The primary outcome was SL’s yield, defined as peritoneal status changed by SL over all SLs.
Results
Among 182 cM+ patients who received SL, 38 (20.9%) had SL-findings changing peritoneal status. Notably, 10.1% of cases with preoperative signs of carcinomatosis had no peritoneal disease, while 46.3% with extraperitoneal disease alone had peritoneal carcinomatosis (PC) at SL. Thirty-one patients (17.0%) underwent R0 resection: 17 (54.8%) with PC, 3 (9.7%) with liver metastases, 4 (12.9%) with PC and nodal metastases, 2 (6.4%) with lung, and 1 (3.2%) with bone metastases. Seventeen patients with suspected preoperative PC underwent curative treatment: 9 had peritoneal disease ruled out by SL, while the other 8 had limited PC, allowing R0 resection. Logistic regression revealed an inverse correlation between diffuse histotype and absence of PC at SL in patients with peritoneal involvement at imaging (p = 0.02).
Conclusion
SL aids in directing cM+ GC patients to appropriate treatment, with a 20.9% yield. For those with peritoneal involvement at imaging, SL helps identify candidates for curative treatment. In patients with extraperitoneal disease, SL should be considered to assess potential radical strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical and Surgical Sciences, Morgagni-Pierantoni Hospital, University of Bologna, Forlì, Italy.
- Department of General Surgery, Morgagni-Pierantoni Hospital, Forlì, Italy.
- General and Upper GI Surgery Division, University of Verona, Verona, Italy.
- Department of Surgery, University of Siena, Siena, Italy.
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
- Department of Surgery, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy.
Zitieren
APA
Solaini, L., Filippini, F., Marrelli, D., Milone, M., Graziosi, L., Realis Luc, M., Gualtierotti, M., Sofia, S., Rosa, F., Bencivenga, M., Alfieri, S., Ferrari, G., Reddavid, R., De Pascale, S., Donini, A., De Palma, G., Roviello, F., Morgagni, P., & Ercolani, G. (2025). The Role of Staging Laparoscopy in Stage IV Gastric Cancer Patients. Digestive Surgery. https://doi.org/10.1159/000543489
Vancouver
Solaini L, Filippini F, Marrelli D, Milone M, Graziosi L, Realis Luc M, et al. The Role of Staging Laparoscopy in Stage IV Gastric Cancer Patients. Digestive Surgery. 2025. doi:10.1159/000543489
BibTeX
@article{Solaini2025,
author = {Solaini, Leonardo and Filippini, Federica and Marrelli, Daniele and Milone, Marco and Graziosi, Luigina and Realis Luc, Marco and Gualtierotti, Monica and Sofia, Silvia and Rosa, Fausto and Bencivenga, Maria and Alfieri, Sergio and Ferrari, Giovanni and Reddavid, Rossella and De Pascale, Stefano and Donini, Annibale and De Palma, Giovanni and Roviello, Franco and Morgagni, Paolo and Ercolani, Giorgio},
title = {The Role of Staging Laparoscopy in Stage IV Gastric Cancer Patients},
journal = {Digestive Surgery},
year = {2025},
doi = {10.1159/000543489}
}
EUVIMED